PRESS RELEASE

innate pharma

INNATE PHARMA TO SHARE NEW LONG-TERM DATA ON LUMOXITI AT 2019 AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

Long-term data analysis will expand on previously reported efficacy results from Lumoxiti Phase III trial

Marseille, France, November 7, 2019, 7:00 AM CET

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("**Innate**" or the "**Company**") will share new, long-term data from the pivotal Phase III trial of Lumoxiti® (moxetumomab pasudotox) at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, December 7-10.

"At this year's ASH, we look forward to providing important new follow-up data from the Lumoxiti phase III trial and engaging with the hemato-oncology community on improving treatment outcomes for patients with relapsed or refractory hairy cell leukemia," **commented Pierre Dodion, MD, Executive Vice President and Chief Medical Officer of Innate Pharma.**

Details of the poster presentation at ASH are as follows:

- **Moxetumomab Pasudotox-tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial, [poster#2808]**
  Authors: Robert J Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak, Philipp D le Coutre, Bjørn T Gjertsen, Xavier Troussard, Gail J Roboz, Lionel Karlin, Douglas E Gladstone, Nataliya Kuptsova-Clarkson, Shiyao Liu, Priti Patel, Wyndham H Wilson, Ira Pastan, Francis Giles, on behalf of the Study 1053 investigators
  Date: Sunday December 8 | 6:00-8:00 pm ET

About Lumoxiti (moxetumomab pasudotox):

Lumoxiti is a CD22-directed cytotoxin and a first-in-class treatment in the US for adult patients with relapsed or refractory (r/r) hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is not recommended in patients with severe renal impairment (CrCl ≤ 29 mL/min). It comprises the CD22 binding portion of an antibody fused to a truncated pseudomonas exotoxin. The toxin inhibits protein synthesis and ultimately triggers apoptotic cell death. Lumoxiti received U.S. FDA approval in September 2018 and has been granted Orphan Drug Designation by the FDA for the treatment of r/r HCL. AstraZeneca is the current Biologics License Application (BLA) holder for Lumoxiti.

About the '1053' Phase III trial:

The AstraZeneca-sponsored '1053' trial is a single-arm, multicenter Phase III clinical trial assessing the efficacy and safety of Lumoxiti monotherapy in patients with r/r HCL who have received at least two prior therapies, including one purine nucleoside analog. The

trial enrolled 80 patients and was conducted across 34 sites in 14 countries. The primary endpoint was durable complete response (CR), defined as CR with hematologic remission (blood count normalization) for >180 days. Secondary outcome measures included objective response rate, duration of complete and objective response, progression-free survival, safety/tolerability, pharmacokinetics and immunogenic potential.

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	Euronext: IPH Nasdaq: IPHA
LEI	9695002Y8420ZB8HJE29

Disclaimer:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de

Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's final prospectus dated October 16, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investor relations

Innate Pharma
Danielle Spangler
Tel.: +1 917 499 6240
Danielle.Spangler@innate-pharma.fr

Jérôme Marino
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com

Media

Innate Pharma
Tracy Rossin (Global/US)
Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com